How I treat relapsed acute lymphoblastic leukemia in the pediatric population
Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL su...
Uložené v:
| Vydané v: | Blood Ročník 136; číslo 16; s. 1803 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
15.10.2020
|
| ISSN: | 1528-0020, 1528-0020 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL survive long term, and outcomes are much worse with second or later relapses. Recurrences that occur within 3 years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Until recently, treatment options were limited to intensive cytotoxic chemotherapy with or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). In the past decade, several promising immunotherapeutics have been developed, changing the treatment landscape for children with relapsed ALL. Current research in this field is focusing on how to best incorporate immunotherapeutics into salvage regimens and investigate long-term survival and side effects, and when these might replace HSCT. As more knowledge is gained about the biology of relapse through comprehensive genomic profiling, incorporation of molecularly targeted therapies is another area of active investigation. These advances in treatment offer real promise for less toxic and more effective therapy for children with relapsed ALL, and we present several cases highlighting contemporary treatment decision-making. |
|---|---|
| AbstractList | Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL survive long term, and outcomes are much worse with second or later relapses. Recurrences that occur within 3 years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Until recently, treatment options were limited to intensive cytotoxic chemotherapy with or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). In the past decade, several promising immunotherapeutics have been developed, changing the treatment landscape for children with relapsed ALL. Current research in this field is focusing on how to best incorporate immunotherapeutics into salvage regimens and investigate long-term survival and side effects, and when these might replace HSCT. As more knowledge is gained about the biology of relapse through comprehensive genomic profiling, incorporation of molecularly targeted therapies is another area of active investigation. These advances in treatment offer real promise for less toxic and more effective therapy for children with relapsed ALL, and we present several cases highlighting contemporary treatment decision-making. Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL survive long term, and outcomes are much worse with second or later relapses. Recurrences that occur within 3 years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Until recently, treatment options were limited to intensive cytotoxic chemotherapy with or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). In the past decade, several promising immunotherapeutics have been developed, changing the treatment landscape for children with relapsed ALL. Current research in this field is focusing on how to best incorporate immunotherapeutics into salvage regimens and investigate long-term survival and side effects, and when these might replace HSCT. As more knowledge is gained about the biology of relapse through comprehensive genomic profiling, incorporation of molecularly targeted therapies is another area of active investigation. These advances in treatment offer real promise for less toxic and more effective therapy for children with relapsed ALL, and we present several cases highlighting contemporary treatment decision-making.Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL survive long term, and outcomes are much worse with second or later relapses. Recurrences that occur within 3 years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Until recently, treatment options were limited to intensive cytotoxic chemotherapy with or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). In the past decade, several promising immunotherapeutics have been developed, changing the treatment landscape for children with relapsed ALL. Current research in this field is focusing on how to best incorporate immunotherapeutics into salvage regimens and investigate long-term survival and side effects, and when these might replace HSCT. As more knowledge is gained about the biology of relapse through comprehensive genomic profiling, incorporation of molecularly targeted therapies is another area of active investigation. These advances in treatment offer real promise for less toxic and more effective therapy for children with relapsed ALL, and we present several cases highlighting contemporary treatment decision-making. |
| Author | Raetz, Elizabeth A Hunger, Stephen P |
| Author_xml | – sequence: 1 givenname: Stephen P surname: Hunger fullname: Hunger, Stephen P organization: Department of Pediatrics, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA; and – sequence: 2 givenname: Elizabeth A surname: Raetz fullname: Raetz, Elizabeth A organization: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32589723$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUDtPwzAYtFARfcDOhDyyBD6_EmdEFdBKRSwwR479VQ04cYgdof57ChSJ5e6keww3J5MudEjIJYMbxjS_rX0I7oYDKwEkSHFCZkxxnQFwmPzTUzKP8Q2AScHVGZkeUJcFFzPytAqfdE3TgCbRAb3pIzpq7JiQ-n3b70LtTUyNpR7Hd2wbQ5uOph3SHl1j0nBw-tCP3qQmdOfkdGt8xIsjL8jrw_3LcpVtnh_Xy7tNZqXSKVOisLktXVnUlglVyxLBcVXmNnfaWSudUWC3Ukshihw5MxxgW4PGn5LgC3L9u9sP4WPEmKq2iRa9Nx2GMVZcMs245vo7enWMjnWLruqHpjXDvvq7gH8BGkpgYQ |
| CitedBy_id | crossref_primary_10_1002_pbc_31528 crossref_primary_10_1186_s12887_024_05015_3 crossref_primary_10_1016_j_prp_2024_155635 crossref_primary_10_1111_ijlh_14100 crossref_primary_10_1080_08880018_2024_2368007 crossref_primary_10_1097_MPH_0000000000002377 crossref_primary_10_1136_bmjopen_2023_083782 crossref_primary_10_1155_2023_2702882 crossref_primary_10_3389_fonc_2022_1022979 crossref_primary_10_1002_pbc_31092 crossref_primary_10_1016_j_jtct_2024_11_016 crossref_primary_10_3389_fimmu_2023_1280759 crossref_primary_10_3389_fonc_2024_1478888 crossref_primary_10_3389_fped_2022_923419 crossref_primary_10_3390_jcm12144637 crossref_primary_10_1016_j_jtct_2022_05_037 crossref_primary_10_3389_fimmu_2023_1237738 crossref_primary_10_3389_fped_2022_1034373 crossref_primary_10_1002_cncr_33609 crossref_primary_10_3389_fphar_2022_1032664 crossref_primary_10_1038_s41598_022_14364_x crossref_primary_10_1002_adma_202313955 crossref_primary_10_1038_s41408_024_01180_x crossref_primary_10_1002_pbc_28870 crossref_primary_10_1002_pbc_29683 crossref_primary_10_1182_blood_2020008955 crossref_primary_10_3389_fonc_2022_1022901 crossref_primary_10_1186_s12935_021_01870_7 crossref_primary_10_1016_j_clml_2022_12_011 crossref_primary_10_1002_gcc_70045 crossref_primary_10_3390_ijms25126380 crossref_primary_10_3389_fimmu_2025_1531145 crossref_primary_10_1007_s12032_022_01697_w crossref_primary_10_3390_ijms24043860 crossref_primary_10_1002_pbc_31983 crossref_primary_10_3390_cimb47050381 crossref_primary_10_3389_fcimb_2022_981220 crossref_primary_10_1182_blood_2021012392 crossref_primary_10_1080_15384047_2025_2460252 crossref_primary_10_1080_17474086_2023_2298732 crossref_primary_10_3389_fped_2022_1100404 crossref_primary_10_3390_cancers14020426 crossref_primary_10_3389_fped_2021_795833 crossref_primary_10_1007_s13312_024_3293_y crossref_primary_10_1097_MPH_0000000000002765 crossref_primary_10_3389_fped_2021_782785 crossref_primary_10_3390_cancers14246026 crossref_primary_10_3390_ijms22168996 crossref_primary_10_1002_pbc_31733 crossref_primary_10_1186_s42269_023_00999_x crossref_primary_10_1186_s13052_025_01921_z crossref_primary_10_62347_YDNO1939 crossref_primary_10_1038_s41419_025_07981_7 crossref_primary_10_1002_pbc_30401 crossref_primary_10_1186_s40164_023_00435_w crossref_primary_10_1007_s12098_023_04731_5 crossref_primary_10_3389_fonc_2023_1252512 crossref_primary_10_1097_CM9_0000000000003396 crossref_primary_10_1002_cam4_71159 crossref_primary_10_3390_biomedicines11102693 crossref_primary_10_3389_fimmu_2022_915590 crossref_primary_10_1002_jbt_23456 crossref_primary_10_1002_hem3_111 crossref_primary_10_3389_fimmu_2024_1341255 crossref_primary_10_3389_fonc_2024_1405347 crossref_primary_10_1097_MOH_0000000000000685 crossref_primary_10_1038_s41571_022_00607_3 crossref_primary_10_1002_pbc_29091 crossref_primary_10_1093_jncics_pkae063 crossref_primary_10_1016_j_ejcped_2024_100200 crossref_primary_10_1007_s12185_023_03609_8 crossref_primary_10_1002_pbc_31050 crossref_primary_10_1111_bjh_19390 crossref_primary_10_3390_cancers13225814 crossref_primary_10_3390_ijms242316708 crossref_primary_10_1007_s12185_024_03838_5 crossref_primary_10_1158_0008_5472_CAN_23_3804 crossref_primary_10_1093_immadv_ltaf025 crossref_primary_10_1007_s00608_023_01154_5 crossref_primary_10_3389_fped_2024_1488686 crossref_primary_10_1182_blood_2025028938 crossref_primary_10_3389_fped_2021_784024 crossref_primary_10_1080_17474086_2025_2528886 crossref_primary_10_1182_bloodadvances_2022008280 crossref_primary_10_1016_j_drup_2024_101141 crossref_primary_10_1016_j_ncrna_2025_09_005 crossref_primary_10_1182_bloodadvances_2021005579 crossref_primary_10_1038_s41375_024_02395_4 crossref_primary_10_1111_bjh_20007 crossref_primary_10_3389_fped_2022_980234 crossref_primary_10_1016_j_biopha_2023_115936 crossref_primary_10_7759_cureus_49930 crossref_primary_10_1080_08880018_2023_2209158 crossref_primary_10_1080_16078454_2024_2412952 crossref_primary_10_1186_s13046_024_03199_1 crossref_primary_10_1002_cpt_3022 crossref_primary_10_3389_fimmu_2022_921894 crossref_primary_10_1055_s_0044_1779048 crossref_primary_10_3390_jcm10163556 crossref_primary_10_1111_bjh_70014 crossref_primary_10_1002_pbc_30335 crossref_primary_10_1182_blood_2021014495 crossref_primary_10_1111_ejh_14092 crossref_primary_10_3389_fimmu_2024_1423487 crossref_primary_10_3390_biomedicines13061412 crossref_primary_10_1097_MPH_0000000000002727 crossref_primary_10_2478_raon_2024_0006 crossref_primary_10_1093_jnci_djaf024 crossref_primary_10_3390_cancers14010150 crossref_primary_10_1016_j_biopha_2025_118436 crossref_primary_10_1155_2022_6057017 crossref_primary_10_1002_pbc_30841 crossref_primary_10_1016_j_eclinm_2025_103211 crossref_primary_10_1177_20406207231201454 crossref_primary_10_3390_biomedicines9111621 crossref_primary_10_1155_2024_2239888 crossref_primary_10_3389_fonc_2024_1498409 crossref_primary_10_1038_s41375_024_02403_7 crossref_primary_10_1186_s13039_024_00682_4 crossref_primary_10_1515_cclm_2024_1503 |
| ContentType | Journal Article |
| Copyright | 2020 by The American Society of Hematology. |
| Copyright_xml | – notice: 2020 by The American Society of Hematology. |
| DBID | NPM 7X8 |
| DOI | 10.1182/blood.2019004043 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 32589723 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 AALRI ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c458t-537c6c9d97bc135b49e0d2596c6d8dcc4da50cf4843376e21a200fb08ec9d9732 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 148 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000579877100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Thu Oct 02 18:42:51 EDT 2025 Thu Apr 03 06:56:34 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Language | English |
| License | 2020 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c458t-537c6c9d97bc135b49e0d2596c6d8dcc4da50cf4843376e21a200fb08ec9d9732 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Review-5 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://ashpublications.org/blood/article-pdf/136/16/1803/1761205/bloodbld2019004043c.pdf |
| PMID | 32589723 |
| PQID | 2418128283 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2418128283 pubmed_primary_32589723 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-15 |
| PublicationDateYYYYMMDD | 2020-10-15 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2020 |
| SSID | ssj0014325 |
| Score | 2.6473906 |
| SecondaryResourceType | review_article |
| Snippet | Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1803 |
| Title | How I treat relapsed acute lymphoblastic leukemia in the pediatric population |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32589723 https://www.proquest.com/docview/2418128283 |
| Volume | 136 |
| WOSCitedRecordID | wos000579877100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwEB0BZbuwlK1sMhLiZjWLkzgnBIiqHFr1AFJvVTKxpQpIAm1B_D1jN6EnJCQuUS52Es945s3iPIBLgV7sonK5KyKHC50iT9D1OWpN6DlKY0cnlmwi6vflcBgPqoTbpGqrrG2iNdRZgSZH3iZPQ76I4gP_unzjhjXKVFcrCo1laPgEZYxWR8NFFUH4lnSVXJTkBhfVZUrptW1buOnsio0amzM7vwFM62g62_99xR3YqiAmu5nrxC4sqbwJezc5hdevX-yK2aZPm01vwtptfbdxV1O_NWG9V1Xc96DXLT7ZA7P96MwcfCknKmMJzqaKvXyRKhQp4W96EntRs2eaIWHjnBGqZGVNAsLKH5KwfXjq3D_edXlFwcBRBHLKAz_CEOMsjlKSYJCKWDkZRUwhhpnMEEWWBA5qIYVPlkp5bkK7TqeOVHaQ7x3ASl7k6giY54YoFGlMGGoyHBiLwNERASIysDLzsAUX9aqO6HNN3SLJVTGbjBbr2oLDuWhG5fxfHCOSsDTEacd_GH0Cm56Jlk0_SnAKDU0bXJ3BKn5Mx5P3c6s7dO0Pet-o185X |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=How+I+treat+relapsed+acute+lymphoblastic+leukemia+in+the+pediatric+population&rft.jtitle=Blood&rft.au=Hunger%2C+Stephen+P&rft.au=Raetz%2C+Elizabeth+A&rft.date=2020-10-15&rft.eissn=1528-0020&rft.volume=136&rft.issue=16&rft.spage=1803&rft_id=info:doi/10.1182%2Fblood.2019004043&rft_id=info%3Apmid%2F32589723&rft_id=info%3Apmid%2F32589723&rft.externalDocID=32589723 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |